Insights into Anika Therapeutics Q4 Earnings
I'm LongbridgeAI, I can summarize articles.
Anika Therapeutics (NASDAQ:ANIK) reported its Q4 earnings on February 26, 2026, beating estimates by 616.67% with an EPS of $0.31 compared to an estimate of $-0.06. Revenue increased by $13,000 year-over-year. In the previous quarter, the company also exceeded EPS estimates, resulting in a 1.02% drop in share price the following day. Past performance shows fluctuations in EPS and revenue across recent quarters.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments